The numbers · Research context only
BPC-157 TB-500 Dosage in the Literature: Per-Component, and Per Species
What was administered, to which species, by which route — and the plain fact that the blend has no validated dose, no validated cycle, and no human pharmacokinetics.
BPC-157 and TB-500 Dose Ranges in Preclinical Studies
<a id="dose-ranges"></a>BPC-157 TB-500 dosage figures come from animal models, expressed per body weight, and they belong to one constituent at a time — there is no validated dose for the blend. The two peptides have never been dose-found together in a controlled study, so any combined number is unanchored.
The BPC-157 component, in rodent studies, is commonly expressed per body weight — frequently around 10 µg/kg and 10 ng/kg in tissue-repair models [1], with gastric-ulcer cytoprotection studied at 400-800 ng/kg in rats. The TB-500 / Thymosin Beta-4 component spans a far wider range: 2-18 mg/kg intraperitoneal in a rat embolic-stroke dose-response study, where the optimal modeled dose was about 3.75 mg/kg and 18 mg/kg gave no benefit at all [4] — a direct demonstration that higher is not better. In the mdx muscular-dystrophy model, Thymosin Beta-4 was given at 150 µg twice weekly intraperitoneally for six months [4].
These are BPC-157 and TB-500 dose ranges from species-specific research designs. They describe what animals received in experiments. They are not human guidance, and they do not convert to a blend protocol.
Routes, half-life, and pharmacokinetics
<a id="routes"></a>### Routes Studied: Subcutaneous, Intramuscular, and Beyond
The predominant research-community routes for the blend are subcutaneous and intramuscular, but those are not drawn from controlled human efficacy trials. The underlying rodent efficacy studies for both peptides used intraperitoneal injection [1], [6]; human Phase 1 work on full-length Thymosin Beta-4 and a BPC-157 safety pilot used intravenous routes; individual-compound wound and tendon models used local, intra-lesional, and topical routes. The phrase wolverine injection describes a research-community practice, not a validated protocol.
<a id="oral-vs-injected"></a>### Oral vs. Injected: What the Literature Does and Does Not Show
BPC-157 is studied as a "stable gastric" peptide and tolerates the gastrointestinal environment in rodent work, which is why bpc 157 tb 500 oral products are marketed [1]. But blend oral products lack validated pharmacokinetics, and the TB-500 fragment has no oral PK data at all. Oral availability for the pair is an assumption inherited from single-compound BPC-157 studies.
<a id="half-life"></a>### What Is the Half-Life of BPC-157 and TB-500?
BPC-157 elimination half-life was reported under 30 minutes in a rat/dog pharmacokinetic study. No validated human half-life exists for the TB-500 heptapeptide or for the blend; human intravenous full-length Thymosin Beta-4 showed dose-proportional pharmacokinetics with half-life increasing at higher doses, but no specific figure is established for the 7-mer [4]. The blend's half-life and pharmacokinetics are, in short, uncharacterized in humans.
Cycling, frequency, and reconstitution
How Do You Cycle BPC-157 and TB-500?
No validated cycle exists for the blend. Community "loading then maintenance" protocols and fixed-ratio vials have no controlled-trial basis [10]; the published evidence is per-component and from animal models. A cycle implies a tested schedule the literature has never produced.
How Much BPC-157 and TB-500 Should Be Used Per Week?
There is no validated weekly dose for the blend. Rodent BPC-157 doses are expressed per body weight (around 10 µg/kg) [1] and Thymosin Beta-4 doses span a wide range [4]; these are species-specific research figures, not human guidance, and they do not sum into a weekly stack amount.
How Often Should You Inject BPC-157 and TB-500?
No validated injection frequency exists for the blend. The underlying rodent studies used various schedules — Thymosin Beta-4 twice weekly intraperitoneally in one six-month model [4] — but these are research designs, not human dosing instructions.
How Do You Reconstitute a BPC-157 / TB-500 Blend?
Both constituents are supplied as lyophilized powders reconstituted in bacteriostatic or sterile water and refrigerated for research handling. Product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed [9] — a caveat that compounds the existing fragment-versus-full-length identity gap around TB-500.